Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00570336
Other study ID # CTS-1027-01
Secondary ID
Status Completed
Phase Phase 2
First received December 6, 2007
Last updated September 14, 2010
Start date December 2007
Est. completion date July 2009

Study information

Verified date September 2010
Source Conatus Pharmaceuticals Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if CTS-1027 can lower elevated liver enzymes in patients with chronic HCV infection.


Description:

Randomized, placebo-controlled, double-blind, parallel group, multicenter, dose response trial utilizing four doses of CTS-1027, administered orally once daily, in outpatients with chronic hepatitis C virus (HCV) infection.


Recruitment information / eligibility

Status Completed
Enrollment 87
Est. completion date July 2009
Est. primary completion date July 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female patients of minimum adult legal age (according to local laws for signing the informed consent document), able to provide written informed consent, and understand and comply with the requirements of the trial

- A history of chronic HCV infection

- Unsuccessful HCV treatment defined as one or more of the following criteria:

1. Failure to achieve a virologic response during previous therapy, or

2. Failure to tolerate therapy, or

3. Failure to maintain a sustained virologic response, or

4. In the opinion of the Principal Investigator, the patient is not a suitable candidate for interferon based therapy

- Liver impairment, as defined by either aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) levels 1.5 - 7 x ULN on at least two occasions, seven or more days apart, during the baseline period

- Alpha-fetoprotein (AFP) <= 50 ng/mL

- Hemoglobin >= 10 g/dL, platelet count >= 75 x 109/L, and white blood cell count >= 1.5 x 109/L

- Willingness to utilize adequate contraception (if female, evidenced by being postmenopausal for at least 6 months or using contraceptive pill; for both females and males, being surgically sterile, or using two forms of barrier contraception) from screening to at least one month after the completion of the trial.

Exclusion Criteria:

- Decompensated or severe liver disease defined by one or more of the following criteria:

1. Prior liver biopsy showing cirrhosis

2. Prior liver biopsy showing bridging fibrosis (Metavir >2 or Ishak >3) more than 2 years ago in the absence of newer liver biopsy results

3. Prothrombin time: 3 seconds > control

4. Total bilirubin >= 1.5 x Upper limit of the normal range (ULN), or > 3 x ULN for unconjugated bilirubin

5. Serum albumin below normal limits

6. AST or ALT > 7 x ULN during baseline period

7. Evidence of portal hypertension including:

- Splenomegaly or evidence of portal hypertension (i.e., enlarged portal vein and varices) on ultrasound,

- Varices in esophagogastroduodenoscopy (EGD); or

- Ascites

- Hepatocellular carcinoma (HCC) or suspicion of HCC clinically or on ultrasound (or other imaging techniques)

- Known history or presence of human immunodeficiency virus (HIV) infection

- Co-infection with hepatitis B virus (HBV)

- If female: pregnant, lactating, or positive serum or urine pregnancy test

- Last baseline AST and ALT level prior to Day 1 of < 1.5 x ULN

- Renal impairment (creatinine > 1.5 x ULN) or hepatorenal syndrome

- Pancreatitis

- Hospitalization for liver disease within 60 days of screening

- Use of concomitant or prior drug therapy for HCV at screening, including the use of:

1. drugs with presumed anti-HCV activity in the prior three months

2. corticosteroids in the past 30 days

3. potentially hepatotoxic drugs in the past 30 days (including alpha methyl-dopa, sodium valproic acid, isoniazide, or nitrofurantoin)

- Use of illicit or drugs of abuse in the prior three months (allowed if medically prescribed or indicated)

- History of alcohol abuse within the past year

- History or presence of clinically concerning cardiac arrhythmias or prolongation of pre-dose QT or QTc interval of > 450 milliseconds

- Other concomitant disease or condition likely to significantly decrease life expectancy (e.g., moderate to severe congestive heart failure) or any malignancy other than curatively treated skin cancer (basal cell or squamous cell carcinomas), unless adequately treated or in complete remission for ten or more years

- Any patient who has received any investigational drug or device within 30 days of dosing, or who is scheduled to receive another investigational drug or device during the course of this trial.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
CTS-1027
Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).
Other:
Placebo
Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd.

Locations

Country Name City State
United States Digestive Healthcare of Georgia Atlanta Georgia
United States University of Colorado Denver Aurora Colorado
United States University of Alabama at Birmingham Birmingham Alabama
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Bronx VA Medical Center Bronx New York
United States Consultants of Clinical Research Cincinnati Ohio
United States Cleveland Clinic Cleveland Ohio
United States Duke University Medical Center Durham North Carolina
United States Advanced Liver Therapies - Baylor College of Medicine Houston Texas
United States VAMC - Baylor College of Medicine Houston Texas
United States Scripps Clinic La Jolla California
United States University of Miami Miami Florida
United States Tulane University Health Sciences Center New Orleans Louisiana
United States Mt. Sinai School of Medicine New York New York
United States McGuire Hospital DVAMC Richmond Virginia
United States Mayo Clinic Rochester Minnesota
United States Kaiser Permanente San Diego California
United States California Pacific Medical Center San Francisco California
United States Henry Ford Health System West Bloomfield Michigan

Sponsors (2)

Lead Sponsor Collaborator
Conatus Pharmaceuticals Inc. FGK Clinical Research GmbH

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of adverse events at each dose level 4 to 24 weeks Yes
Primary Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) levels at each dose 4-24 Weeks Yes
Secondary Peak and trough levels of CTS-1027 in plasma 4 to 24 weeks Yes
See also
  Status Clinical Trial Phase
Completed NCT01708889 - Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction Phase 1
Active, not recruiting NCT00563173 - Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients Phase 1/Phase 2
Withdrawn NCT01813266 - Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors
Completed NCT01121731 - A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C Phase 1/Phase 2
Completed NCT00851890 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection Phase 2
Completed NCT04391985 - Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients Phase 1/Phase 2
Completed NCT04387539 - ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants Phase 1/Phase 2
Completed NCT00770198 - sgp130 in Chronic Human Liver Disease N/A
Completed NCT04382937 - Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection Phase 3
Completed NCT00606528 - FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy N/A
Recruiting NCT00294489 - Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT Phase 3
Withdrawn NCT00255359 - Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers Phase 1
Completed NCT02292719 - A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection Phase 2
Terminated NCT01080222 - A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection Phase 2
Completed NCT04385407 - Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients Phase 2
Completed NCT04387526 - Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4 Phase 2/Phase 3
Completed NCT00215865 - PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy Phase 3